Age-related immune states and PD-1 blockade: mechanisms and strategies for the elderly
Journal for ImmunoTherapy of Cancer · 2025-12 · 13 (12) · e013783
DOI: 10.1136/jitc-2025-013783 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 01.12.2025. Verfasst von Tomonori Yaguchi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology (CCII), Kyoto University Graduate School of Medicine…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors, Aging, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Meiji Seika Pharma Co., Ltd., AMED, JSPS KAKENHI.
Abstract (Originalsprache)
Aging impairs antitumor immunity and may reduce the efficacy of immune checkpoint inhibitors (ICIs). However, the underlying mechanisms remain unclear. Building on our recent findings, we review three key mechanisms of CD8 + T-cell aging: elevated T-cell receptor (TCR) activation thresholds, mitochondrial dysfunction, and disruption of proteostasis. Studies in aged mice have revealed that aged naïve T cells exhibit defective priming due to increased CD45 expression, which raises the TCR activation threshold and restricts effector differentiation. Aging also impairs mitochondrial metabolism, particularly fatty acid oxidation. Furthermore, we highlight the role of proteostasis collapse, including defective autophagy and increased endoplasmic reticulum stress, as a contributor to T-cell dysfunction. Spermidine, a polyamine that declines with age, has the potential to modulate both mitochondrial function and proteostasis. Its supplementation has been shown to improve programmed cell death-1 blockade responsiveness in aged mice. Although clinical studies in humans have yielded inconsistent results regarding the effect of chronological age on ICI efficacy, identifying patients with “age-related” immune microenvironments may enable stratified therapeutic approaches based on insights from preclinical aging models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology (CCII), Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Immuno-oncology PDT, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Immune Metabolism, Center for Cancer Immunotherapy and Immunobiology (CCII), Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Immunology and Genomic Medicine, Center for Cancer Immunotherapy and Immunobiology (CCII), Kyoto University Graduate School of Medicine, Kyoto, Japan honjo.tasuku.6w@kyoto-u.ac.jp.
Förderung
- Meiji Seika Pharma Co., Ltd.
- AMED
- JSPS KAKENHI
- Yanai Fund
- Meiji Holdings Co., Ltd.
Zitieren
APA
Yaguchi, T., Chamoto, K., & Honjo, T. (2025). Age-related immune states and PD-1 blockade: mechanisms and strategies for the elderly. Journal for ImmunoTherapy of Cancer, 13(12), e013783. https://doi.org/10.1136/jitc-2025-013783
Vancouver
Yaguchi T, Chamoto K, Honjo T. Age-related immune states and PD-1 blockade: mechanisms and strategies for the elderly. Journal for ImmunoTherapy of Cancer. 2025;13(12):e013783. doi:10.1136/jitc-2025-013783
BibTeX
@article{Yaguchi2025,
author = {Yaguchi, Tomonori and Chamoto, Kenji and Honjo, Tasuku},
title = {Age-related immune states and PD-1 blockade: mechanisms and strategies for the elderly},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {12},
pages = {e013783},
doi = {10.1136/jitc-2025-013783}
}
EUVIMED